<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080924</url>
  </required_header>
  <id_info>
    <org_study_id>08/10 Pabes</org_study_id>
    <nct_id>NCT01080924</nct_id>
  </id_info>
  <brief_title>Demonstration of Broncholytic Effects in Subjects With Obstructive Airway Diseases by Low Frequency Ultrasound</brief_title>
  <acronym>Pabes</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fraunhofer-Institute of Toxicology and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Pharmacology and Toxicology, RWTH Aachen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fraunhofer-Institute of Toxicology and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aiming at evaluating whether low frequency ultrasound spectroscopy is a&#xD;
      sensitive tool to detect broncholytic effects in patients with obstructive airway diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• change of the difference of expiratory and inspiratory TOF Expectation: The difference of ex and inspiratory TOF should increase after broncholysis. A change above 10us will be considered significant</measure>
    <time_frame>10 minutes post broncholysis</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>COPD GOLD I to IV</condition>
  <condition>Asthma GINA 1 to 4</condition>
  <arm_group>
    <arm_group_label>Low frequency ultrasound spectroscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low frequency ultrasound spectroscopy after broncholysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low frequency ultrasound spectroscopy after broncholysis</intervention_name>
    <description>Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.</description>
    <arm_group_label>Low frequency ultrasound spectroscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • 18 - 70 years&#xD;
&#xD;
               -  for the healthy cohort:&#xD;
&#xD;
                    -  FEV1 &gt; 80 % pred, FEV1/FVC ≥ 70 % pred., no history of allergies or asthma&#xD;
&#xD;
                    -  nonsmokers, with a history of less than 1 packyear having been nonsmokers&#xD;
                       for at least the last five years&#xD;
&#xD;
               -  for the COPD cohort: COPD GOLD I to IV according to current guidelines (2)&#xD;
&#xD;
               -  for the asthma cohort: history of asthma GINA I to IV according to current&#xD;
                  guidelines (3)&#xD;
&#xD;
               -  BMI ≤ 30 kg/m2&#xD;
&#xD;
               -  Able and willing to give written informed consent&#xD;
&#xD;
               -  Available to complete all study measurements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • medical conditions which prohibit the use of salbutamol&#xD;
&#xD;
               -  recent exacerbation of COPD or asthma or lower respiratory tract infection (four&#xD;
                  weeks previous to informed consent visit)&#xD;
&#xD;
               -  past or present disease, which as judged by the investigator, may affect the&#xD;
                  outcome of the study. These diseases include, but are not limited to,&#xD;
                  cardiovascular disease, malignancy, hepatic disease, renal disease, hematological&#xD;
                  disease, neurological disease, psychiatric disease, endocrine disease or&#xD;
                  pulmonary disease (including but not confined to asthma, tuberculosis,&#xD;
                  bronchiectasis or cystic fibrosis)&#xD;
&#xD;
               -  history of drug or alcohol abuse which would interfere with the subject's proper&#xD;
                  completion of the protocol assignment&#xD;
&#xD;
               -  risk of non-compliance with study procedures&#xD;
&#xD;
               -  suspected inability to understand the protocol requirements, instructions and&#xD;
                  study-related restrictions, the nature, scope, and possible consequences of the&#xD;
                  study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Hohlfeld, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fraunhofer Institute for Toxicology and Experimental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fraunhofer ITEM</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>March 3, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Jens Hohlfeld</name_title>
    <organization>Fraunhofer-Institute of Toxicology and Experimental Medicine</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

